Clinical Trials Directory

Trials / Completed

CompletedNCT00940927

Dose-response of Albuterol in Asthmatics

Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
81 (actual)
Sponsor
Nemours Children's Clinic · Academic / Other
Sex
All
Age
8 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to determine the lung function response after increasing doses of albuterol (a bronchodilator) in children and adults with asthma.

Detailed description

Inhaled short-acting b2-agonists (SABA) are the most potent bronchodilators used today to treat acute symptoms of asthma and albuterol, a partial b2-agonist, is the most frequently prescribed asthma medication in the US. Although universally used in for acute asthma symptoms, SABA have been associated with a significant degree of interpatient variability. Many studies have characterized the SABA dose to bronchodilator response relationship under controlled conditions. However, few studies have explored the magnitude and sources of bronchodilator response variability, and no studies have characterized the dose versus bronchodilator response relationship using population pharmacokinetic/pharmacodynamic (PPK/PD) modeling. In the present study, we characterized the relationship between inhaled doses of albuterol and bronchodilation in 81 children and adults with moderate to severe persistent asthma using a population pharmacodynamic approach. The purpose of this study was to obtain estimates of the pharmacodynamic parameters that characterize the dose-response curve, including maximal dose for bronchodilation, and to quantify and identify sources of interpatient pharmacodynamic variability.

Conditions

Interventions

TypeNameDescription
DRUGalbuterolAlbuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)

Timeline

Start date
1993-07-01
Primary completion
1994-10-01
Completion
1994-10-01
First posted
2009-07-17
Last updated
2015-05-05
Results posted
2009-07-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00940927. Inclusion in this directory is not an endorsement.